Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Trump Administration: Seven More Things To Watch Out For

Executive Summary

Beyond pricing, industry experts weigh in on how the next administration has shifted expectations across a range of areas – including tax reform, FDA standards and the Cancer Moonshot Initiative.

You may also be interested in...



Flu Hunters: House Committee Searches For Pandemic Plan

Update to 2005 outline of US response to pandemic influenza was due at the end of 2016, but has yet to be released.

On The Sunny Side Of Trump Street: Biopharma Ready For Tax Reform

Industry experts expressed optimism for tax reform at the Biotech Showcase and J.P. Morgan Healthcare Conference, though there is concern about the future of the federal Small Business Innovation Research program.

Trump Makes A Nasty News Day For Pharma – But What Will It Really Mean?

President-elect threatens a government bidding process to control drug pricing in his first post-election press conference.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS119815

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel